Sun Pharmaceutical Industries reported strong consolidated numbers for Q4 FY26, with net profit rising 26 per cent year-on-year to 2,714 crore, despite continued weakness in its US generics business. Growth in innovative medicines and increased R&D investments are helping to offset these pressures.
Sun Pharmaceutical Industries Ltd has announced its acquisition of US-based Organon & Co in an all-cash deal valued at an enterprise valuation of USD 11.75 billion, aiming to become a top 25 global pharmaceutical company.
Sun Pharmaceutical Industries' Executive Chairman Dilip Shanghvi described the USD 11.75 billion acquisition of US-based Organon & Co as both a "happy" and "bit anxious" moment, acknowledging the significant debt required to fund the large transaction.
Sun Pharmaceutical Industries reported a 27 per cent year-on-year increase in consolidated net profit to 2,894.7 crore for Q1FY27, with revenue growing 10 per cent to 15,299.8 crore, driven by strong performance in India and innovative medicines.
Indian benchmark indices Sensex and Nifty opened the special Muhurat trading session on a bullish note, marking the beginning of the Hindu calendar Samvat 2083, driven by buying in key blue-chip stocks.
Indian benchmark indices Sensex and Nifty rebounded in early trade after three days of decline, driven by a rally in Sun Pharma following its USD 11.75 billion acquisition of US-based Organon & Co, alongside a positive trend in global equity markets.
Indian benchmark indices Sensex and Nifty extended their rally in early trade, driven by strong buying in IT firms and an earnings-driven surge in Tata Group's retail arm, Trent, which reported a 25 per cent increase in net profit.
Indian benchmark equity indices, Sensex and Nifty, rallied in early trade, driven by sustained foreign fund inflows and a decline in crude oil prices. Foreign Institutional Investors (FIIs) have shown aggressive buying, investing a significant amount in Indian equities, while positive Q2 earnings and lower Brent crude prices are further supporting the market's upward trend. Track Sensex, Nifty on November 12, 2026.
Indian stock markets are set to be influenced this week by a confluence of factors including quarterly corporate earnings, the US Federal Reserve's interest rate decision, fluctuations in crude oil prices, and ongoing geopolitical developments in West Asia.
Indian equity benchmark indices Sensex and Nifty slumped in early trade, ending a three-day rally, as profit-taking combined with concerns over surging retail inflation, which breached the Reserve Bank of India's upper tolerance limit, leading to anticipation of a policy rate hike. Track Sensex, Nifty on November 13.
Indian benchmark indices, Sensex and Nifty, saw significant gains in early trade, primarily driven by a strong performance from Reliance Industries following its record quarterly profit announcement and a notable decline in global crude oil prices. Positive foreign fund inflows and a buoyant trend in Asian markets further contributed to the market's optimism.Track Sensex, Nifty on November 2.
Indian benchmark indices Sensex and Nifty extended their winning streak in early trade, with Sensex jumping 614.66 points and Nifty rallying 149.80 points. This surge is attributed to a sharp correction in crude oil prices, continued foreign fund inflows, and positive Q2 results, creating an ideal environment for the market rally to continue.
Indian benchmark indices Sensex and Nifty ended marginally lower in the special Diwali Muhurat trading session, snapping a seven-day rally amid profit-taking by investors. Despite a positive start, the Sensex dipped 28.62 points to 80,999.40, and the Nifty declined 43.95 points to 24,986.40.
Indian benchmark indices, Sensex and Nifty, closed significantly higher, with the Sensex rallying 1,233 points and the Nifty climbing to 23,440.80. This surge was primarily fuelled by a sharp increase in Reliance Industries' share price following strong quarterly earnings and a notable decline in crude oil prices.
A strong third-quarter (October-December/Q3) performance for 2025-26 (FY26) has helped the stock of India's largest listed pharmaceutical (pharma) company, Sun Pharmaceutical Industries, gain about 7 per cent since the start of February.
Indian benchmark equity indices, Sensex and Nifty, experienced a decline in early trade due to elevated crude oil prices, ongoing geopolitical uncertainties, and investor caution ahead of the US Federal Reserve's policy decision later this week. Track Sensex, Nifty on October 26.
Indian benchmark indices, Sensex and Nifty, recovered early losses on Wednesday, driven by strong buying in IT stocks and HDFC Bank, sustaining the previous session's recovery despite FII outflows. Track Sensex, Nifty on October 14.
Indian benchmark indices, Sensex and Nifty, closed lower on Tuesday, with the Sensex declining 329.91 points to 74,529.08 and the Nifty dipping 85.30 points to 23,329, primarily dragged by underperformance in IT, financial, and capital goods stocks despite positive global market trends and easing crude oil prices.
Indian benchmark indices, Sensex and Nifty, ended marginally lower after recovering from sharp intraday losses, driven by cooling crude oil prices and buying interest in HDFC Bank and IT sector stocks.
India's 10 largest pharmaceutical companies have consistently maintained positive average volume growth throughout 2026, while smaller rivals have experienced more erratic performance, driven by a market shift towards chronic and sub-chronic therapies.
Indian benchmark indices Sensex and Nifty rebounded in early trade after two days of losses, driven by easing crude oil prices and strong buying in blue-chip IT stocks, despite continued global uncertainties. Track Sensex, Nifty on September 30.
Indian equity benchmark indices, Sensex and Nifty, extended their losses for a second consecutive day, driven by elevated crude oil prices, persistent foreign institutional investor (FII) outflows, and high US Treasury yields.
Indian equity benchmark indices Sensex and Nifty experienced a significant tumble in early trade, primarily driven by elevated crude oil prices due to ongoing West Asia uncertainty and substantial foreign fund outflows. Track Sensex, Nifty on September 29.
Indian benchmark indices Sensex and Nifty saw a significant rebound in early trade, with the Sensex surging over 700 points, driven by a decline in crude oil prices, easing concerns over Federal Reserve tightening, and the appointment of Anup Bagchi as the new MD and CEO of HDFC Bank.
Indian benchmark indices Sensex and Nifty extended their losses for a third consecutive day, driven by firm crude oil prices, elevated global bond yields, and significant foreign fund outflows, making investors cautious.
Sun Pharmaceutical Industries' acquisition of US-based Organon & Co. for $11.75 billion, the largest overseas acquisition by an Indian pharma company, has been met with mixed reactions from brokerages, who see strategic entry into women's health and biosimilars but also flag potential integration challenges and debt concerns.
Indian benchmark indices, Sensex and Nifty, saw gains in early trade, driven by a notable drop in crude oil prices and renewed buying interest from Foreign Institutional Investors (FIIs).
Indian benchmark equity indices, Sensex and Nifty, closed higher on Monday, driven by softer-than-expected US jobs data which reduced expectations of aggressive monetary tightening by the US Federal Reserve, boosting risk appetite across emerging markets.
Indian benchmark indices Sensex and Nifty opened higher, extending gains from the previous session, driven by a rally in global markets and a slight cooling in crude oil prices. Optimism around a potential meeting between US and Iranian presidents also contributed to positive sentiment.Later both indices pared gains and were trading in red. Track Sensex, Nifty on September 22.
The imposition of a 100 per cent tariff by the US on imports of branded and patented pharmaceutical products starting October 1 may not significantly hurt Indian drug makers, with Sun Pharma being exposed to some headline risk but with limited earnings impact, according to analysts. Among Indian companies, only Sun Pharma has sizeable sales from patented drugs in the US (about 17 per cent of 2024-25 revenue), HSBC Global Investment Research said in a report.
Indian benchmark indices, Sensex and Nifty, experienced a significant drop in early trade, with the Sensex falling over 600 points, primarily due to crude oil prices surging past the USD 100 per barrel mark and weak global market trends. Track Sensex, Nifty on September 24.
Indian benchmark indices, Sensex and Nifty, continued their downward trend for the fifth consecutive day, with the Sensex dropping 281 points and Nifty falling 78 points, primarily driven by surging crude oil prices and persistent geopolitical tensions in West Asia.
The National Stock Exchange marked its stock market debut at the Bombay Stock Exchange on September 24, 2026, with a traditional gong-ringing ceremony.
Indian benchmark indices, Sensex and Nifty, saw declines in early trade due to escalating crude oil prices and ongoing US-Iran hostilities, which subdued investor risk appetite.
Indian benchmark indices, Sensex and Nifty, traded flat in early deals due to elevated crude oil prices exceeding USD 100 per barrel and persistent geopolitical tensions, which subdued investor risk appetite.
Sun Pharmaceutical Industries on Wednesday posted a 2.56 per cent increase in its consolidated net profit to Rs 3,118 crore for the second quarter ended September 30, aided by robust sales in India and emerging markets. The Mumbai-based drug major reported a net profit of Rs 3,040 crore for the July-September quarter of the last fiscal.
Indian benchmark indices, Sensex and Nifty, experienced declines in early trade due to a surge in crude oil prices and significant selling pressure on bank stocks, impacting overall investor sentiment. Track Sensex, Nifty on July 22.
Indian stock markets closed lower due to selling in IT and FMCG shares, triggered by renewed tensions in West Asia which led to a rally in crude oil prices and concerns over inflation and interest rates.
Despite a healthy performance in the fourth quarter of 2024-25 (Q4FY25), the stock of India's largest listed pharma company, Sun Pharmaceutical Industries (Sun Pharma), was under pressure on Friday due to a muted guidance. The company has guided for a high single-digit revenue growth for FY26, which is below what the Street was working with.
Indian benchmark indices Sensex and Nifty experienced a significant slump in early trade, mirroring a bearish trend in global equities, as escalating conflict in West Asia drove up crude oil prices and intensified investor concerns.